Quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a comparison of ponatinib versus imatinib (2025)
- Authors:
- Autor USP: ROCHA, VANDERSON GERALDO - FM
- Unidade: FM
- DOI: 10.1002/cam4.70780
- Subjects: LEUCEMIA MIELOIDE AGUDA; SINAIS E SINTOMAS
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Cancer medicine
- ISSN: 2045-7634
- Volume/Número/Paginação/Ano: v. 14, n. 7, article ID e70780, 9p, 2025
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
ASHAYE, Ajibade et al. Quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a comparison of ponatinib versus imatinib. Cancer medicine, v. 14, n. 7, 2025Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/84773. Acesso em: 27 jan. 2026. -
APA
Ashaye, A., Shi, L., Aldoss, I., Montesinos, P., Vachhani, P., Rocha, V. G., et al. (2025). Quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a comparison of ponatinib versus imatinib. Cancer medicine, 14( 7). doi:10.1002/cam4.70780 -
NLM
Ashaye A, Shi L, Aldoss I, Montesinos P, Vachhani P, Rocha VG, Papayannidis C, Leonard JT, Baer MR, Ribera J-M. Quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a comparison of ponatinib versus imatinib [Internet]. Cancer medicine. 2025 ; 14( 7):[citado 2026 jan. 27 ] Available from: https://observatorio.fm.usp.br/handle/OPI/84773 -
Vancouver
Ashaye A, Shi L, Aldoss I, Montesinos P, Vachhani P, Rocha VG, Papayannidis C, Leonard JT, Baer MR, Ribera J-M. Quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a comparison of ponatinib versus imatinib [Internet]. Cancer medicine. 2025 ; 14( 7):[citado 2026 jan. 27 ] Available from: https://observatorio.fm.usp.br/handle/OPI/84773 - Risk factors affecting outcome of unrelated cord blood transplantation for children with familial haemophagocytic lymphohistiocytosis
- Defining the clinical relevance of red blood cell autoantibodies by Monocyte Monolayer Assay
- Evaluation of a disease risk index for adult patients undergoing umbilical cord blood transplantation for haematological malignancies
- Anticancer cellular immunotherapies derived from umbilical cord blood
- Atrichia with Papular Lesions: importance of histology at an early disease stage
- Low body mass index is associated with increased risk of acute GVHD after umbilical cord blood transplantation in children and young adults with acute leukemia: a study on behalf of Eurocord and the EBMT pediatric disease working party
- The impact of pretransplant malnutrition on allogeneic hematopoietic stem cell transplantation outcomes
- Detection of bacterial contamination in platelet concentrates from Brazilian donors by molecular amplification of the ribosomal 16S gene
- Nonmyeloablative Alternative Donor Transplantation for Hodgkin and Non-Hodgkin Lymphoma: From the LWP-EBMT, Eurocord, and CIBMTR
- BRAF V600E mutation detected in a case of Rosai-Dorfman disease
Informações sobre o DOI: 10.1002/cam4.70780 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
